M.D. Anderson Cancer Center
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Primary Objective: --To determine the intracranial objective response rate (ORR) of niraparib in combination with dostarlimab in patients with brain metastases. Secondary Objectives: * To determine the duration of intracranial response (DoR) of niraparib in combination with dostarlimab in patients with brain metastases. * To determine the intracranial ORR, defined as assessed by RANO-BM and iRANO. * To assess the systemic antitumor activity of niraparib in combination with dostarlimab in patients with brain metastases as defined by ORR, CBR (Stable Disease \[SD\]\>6m+CR+PR), progression fre…
Inclusion Criteria: 1\. Age ≥ 18 years old. 2. Participant must have brain metastasis and either 1\. Advanced BRCA1/2m cancer 2. Advanced HRR-aberrant, non-BRCA1/2m cancer 3. Advanced small cell lung cancer 4. Advanced non-small cell lung cancer 5. Advanced Triple Negative Breast Cancer 3. In cohorts 1 and 2, subjects will be eligible for this study based on the presence of actionable aberrations in one or more of the following HRR genes: BRCA1/2, ATM; BRIP1; CDK12; CHEK1; CHEK2; FANCL; PALB2; RAD51; RAD51B; RAD51C; RAD51D; RAD52; RAD54L, or other related genes at the discretion of the princ…
Given by PO
Given by IV (vein)
Arctuva estimate
Verify or correct the compensation shown for this listing.